Author of

• 17783

  +

  P2.05 - Poster Session with Presenters Present (ID 463)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17814

    +

    P2.05-031 - The Clinical Impact of Different Chemotherapy Regimen Combined with Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (ID 5967)

    14:30 - 14:30  |  Author(s): Y. Chen
    • Abstract
    • Slides

    Background:
    Different chemotherapy regimen have different toxicity for lung. which regimen can improve the therapeutic effect and reduce the toxicity reaction have not reached a consensus. This was a retrospective study to evaluate the clinical toxicity reaction and therapeutic of different chemotherapy regimen combined with radiotherapy for the treatment of locally advanced non-small cell lung cancer (NSCLC).
    
    Methods:
    117 non-small cell lung cancer patients were randomly dividedinto 3 groups,(1) group A( the patients received concurrent chemotherapy consisting of gemcitabine /cisplatin combined with radiotherapy), (2)group B (the patients received concurrent chemotherapy consisting of paclitaxel /cisplatin combined with radiotherapy) and (3) group 3( the patients received the concurrent chemotherapy consisting of Changchun vinorelbine, irinotecan, pemetrexed or other chemotherapeuticdrugs/cisplatin combined with radiotherapy). All the patients received 2-4 cycles chemotherapy, and 2-2.2 Gy per fraction to a total of DT56-66 Gy thoracic radiotherapy 5 times per week.
    
    Results:
    The overall response rate (CR+PR) of the three group was86.7%, 78.7%, 81.5% (x[2]=1.626, P=0.653). The 1-year, 2-year and 3-year progressionfree survival ratesof the three group were: 57.3%, 30.1%, 18.3%; 49%, 33.3%, 18.4% and 39.2%, 27.8%, 16.5% (x2=0.581，P=0.748). The 1-year, 2-year and 3-year overallsurvival rates were 89.3%, 48.5%, 30.3%; 65.5%, 43.3%, 26.8% and 70.3%, 48.3%, 31.6% (x2=1.658，P=0.437). The 1-year, 2-year and 3-year distant metastasis rates were 68%, 38.2%, 21%; 50.3%, 35.3%, 28.1% and 56%, 35.3%, 29.6% (x2=0.559，P=0.756).The incidence of radiation pneumonitis of the 3 group were: 37.5%、24%、20%(x[2]=4.909，P=0.037). In addition, the incidence of radiation esophagitis and bone marrow suppression in the three groups were 26.7%, 18.7%, 14.8 (P=0.832) and 26.7, 50.6%, 33.3%, (P=0.024).
    
    Conclusion:
    The patients received concurrent chemotherapy consisting of gemcitabine /cisplatin combined with radiotherapycould significantly increase the incidence of radiation pneumonitis, the patients received concurrent chemotherapy consisting of paclitaxel /cisplatin combined with radiotherapyalso had a high incidence of radiation pneumonitis. The local control rate and survival rate of the three groups were not statistically different .
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.